<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113789</url>
  </required_header>
  <id_info>
    <org_study_id>20030122</org_study_id>
    <nct_id>NCT00113789</nct_id>
  </id_info>
  <brief_title>Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer</brief_title>
  <official_title>Randomized, Phase 2 Study of Pegfilgrastim Given on the Last Day of a Multi-Day Topotecan Regimen or the Day After in Subjects With Relapsed or Refractory Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This trial will provide data on the safety and efficacy of pegfilgrastim, in terms of
      duration of grade 4 neutropenia, when administered on the last day or the day after a
      multi-day, myelosuppressive chemotherapy regimen for ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Grade 4 Neutropenia</measure>
    <time_frame>During treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PI Discretion</intervention_name>
    <description>PI Discretion</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pegfilgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects with histologically confirmed primary peritoneal carcinoma,
        epithelial ovarian cancer, or tubal carcinoma relapsed after or refractory to 1 or 2 prior
        regimens of therapy - Measurable or evaluable disease - GOG Performance Status of 0 to 2 -
        Subjects must be at least 2 weeks from major surgery and recovered from all associated
        toxicities or sequelae - At least 2 weeks from radiation therapy and recovered from all
        associated toxicities - Adequate hemopoietic function evidenced by: *ANC greater than 1.5 x
        10^9/L, *platelets greater than 100 x 10^9/L and *hemoglobin greater than or equal to 10
        g/dL - AST and ALT less than 1.5 x ULN; total serum bilirubin less than or equal to 2.0
        mg/dL; serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance
        greater than or equal to 60 mL/min Exclusion Criteria: - Epithelial ovarian tumors of low
        malignant potential - Prior therapy with topotecan - Active infection requiring treatment
        with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral
        agent) within 72 hours of chemotherapy - Prior malignancy within the last 5 years, with the
        exception of surgically cured basal/squamous skin cell carcinoma, and/or carcinoma of the
        cervix in-situ - History of impaired cardiac status (e.g., severe heart disease,
        cardiomyopathy, or congestive heart failure) - Any premalignant myeloid condition or any
        malignancy with myeloid characteristics (e.g., myelodysplastic syndromes, acute or chronic
        myelogenous leukemia - Subject is pregnant (e.g., positive HCG test) or breast feeding -
        Subject is of child-bearing potential and does not agree to using adequate contraceptive
        precautions - Any psychiatric, addictive or other kind of disorder which compromises the
        ability of the subject to give written informed consent and/or to comply with study
        protocol procedures - Other investigational procedures are excluded. Subject is currently
        enrolled in, or has not yet completed at least 30 days since ending another investigational
        device or drug trial(s) or is receiving other investigational agent(s)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.neulasta.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2005</study_first_submitted>
  <study_first_submitted_qc>June 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2005</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>topotecan</keyword>
  <keyword>neutropenia</keyword>
  <keyword>NeulastaÂ®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

